Rosetta Genomics Raises $8,000,000 in Private Placement
October 14 2015 - 7:00AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announced it has entered into definitive agreements with investors
to purchase an aggregate of $8,000,000 in units, consisting of
ordinary shares and warrants, in a private placement. The closing
is expected to occur on or about October 16, 2015 and is subject to
the satisfaction of customary closing conditions.
Under the terms of the private placement, Rosetta will sell an
aggregate of 3,333,333 units at $2.40 per unit, with each unit
consisting of (i) one ordinary share, (ii) a Series A Warrant to
purchase one-half of an ordinary share at an exercise price of
$2.75 per ordinary share (subject to adjustment), exercisable for a
period of five years from the closing date, and (iii) a partially
pre-funded Series B Warrant. The Series B Warrants have an exercise
price of NIS 0.6 (which has been prepaid) plus $0.0001 per share.
The Series B Warrants are intended to reset the price of the units,
and will be exercisable for an aggregate number of ordinary shares
based on a reset price per unit equal to 85% of the arithmetic
average of the five lowest weighted average prices calculated
during the ten trading days following the effective date of the
Company’s resale registration statement to be filed for the private
placement; provided that the maximum aggregate number of ordinary
shares issuable upon exercise of the Series B Warrants will not
exceed 2,666,667. The Series B Warrants are exercisable for 60 days
following the effective date of the resale registration statement.
Rosetta is required to file a resale registration statement within
60 days following the closing of the private placement that covers
the resale by the purchasers of the ordinary shares and the
ordinary shares issuable upon exercise of the warrants issued in
the private placement.
Aegis Capital Corp. acted as the exclusive placement agent in
connection with the private placement.
The securities offered and sold in the private placement have
not been registered under the Securities Act of 1933, as amended,
or any state securities laws, and may not be offered or sold in the
United States absent registration, or an applicable exemption from
registration under the Securities Act and applicable state
securities laws.
This announcement is neither an offer to sell nor a solicitation
of an offer to buy any securities of Rosetta.
About Rosetta Genomics
Rosetta develops and commercializes a broad range of
microRNA-based and other high-value molecular diagnostics.
Rosetta’s integrative research platform combining bioinformatics
and state-of-the-art laboratory processes has led to the discovery
of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company also offers core FISH, IHC and
PCR-based testing capabilities and partnerships in oncology and
urology that provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s cancer testing services
are commercially available through the Philadelphia, PA- and Lake
Forest, CA-based CAP-accredited, CLIA-certified labs.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
statements relating to the expected closing of the transaction
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the “Risk Factors” section of Rosetta’s Annual Report
on Form 20-F for the year ended December 31, 2014 as filed with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Rosetta’s views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151014005715/en/
Company:Rosetta GenomicsKen Berlin, 609-419-9003President
& CEOinvestors@rosettagenomics.comorInvestor:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024